Suramin in combination with mitomycin C in hormone-resistant prostate cancer. A phase II clinical study

Rapoport, Bernardo Leon; Falkson, Geoffrey; Raats, Johann; Wet, M. de; Lotz, Barend P.; Potgieter, H. C.

doi:10.1093/oxfordjournals.annonc.a058590

Cited by 17 publications

(3 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Suramin has been evaluated clinically since the early 1980s. At least 33 trials have been published (e.g., [41][42][43][44][45][46][47][48][49][50]. In all of these trials, suramin was used as a cytotoxic agent at therapeutic plasma concentrations of between 100 and 200 mol/L.…”

Section: Discussionmentioning

confidence: 99%

Low-Dose Suramin Enhanced Paclitaxel Activity in Chemotherapy-Naïve and Paclitaxel-Pretreated Human Breast Xenograft Tumors

Song

Yu²,

Wei³

et al. 2004

Clinical Cancer Research

View full text Add to dashboard Cite

We reported induction of broad-spectrum chemoresistance by acidic and basic fibroblast growth factors and chemosensitization by their nonspecific inhibitor suramin at nontoxic and subtherapeutic doses. This study evaluated whether low-dose suramin enhances paclitaxel activity in chemotherapy-naïve and paclitaxel-pretreated human MCF7 breast xenograft tumors in mice. Suramin, 10 mg/kg, and/or paclitaxel, 15 mg/kg, were administered intravenously, twice weekly for 2 to 3 weeks. In addition to conventional end points [tumor size change, median survival time (MST)], we also used clinically relevant end points [partial (PR) and complete response rates (CR); progressive disease (PD); stable disease (SD); time to tumor progression (TTP)]. In chemotherapynaïve mice, the control and suramin groups showed identical TTP (3 days) and MST (21 days). Single-agent paclitaxel produced 47% PR and 24% CR, and prolonged both TTP and MST to 73 days. The addition of suramin further improved the total response rate to 100% with a dramatically greater 63% CR, shortened the time to attain PR and CR, and prolonged TTP and MST to >136 days. In the paclitaxel-pretreated group, single-agent paclitaxel resulted in 67% SD and 33% PD, whereas the combination produced 50% PR and 50% SD. Suramin also significantly enhanced the apoptotic effect of paclitaxel in tumors. In conclusion, suramin improved the activity of paclitaxel in both chemotherapy-naïve and paclitaxel-pretreated animals, without enhancing host toxicity (<10% body weight loss in all groups). These data have led to the initiation of phase I/II trials of paclitaxel and low-dose suramin combination in advanced metastatic breast cancer patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Low-Dose Suramin Enhanced Paclitaxel Activity in Chemotherapy-Naïve and Paclitaxel-Pretreated Human Breast Xenograft Tumors

Song

Yu²,

Wei³

et al. 2004

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…Early results of other studies utilising this approach suggest that the combination can cause disease regression, but further follow-up is necessary before drawing conclu sions on long-term efficacy [24], A number of other methods of hormonal manipula tion are also being investigated. One such approach is has been used with some success in patients with hor mone refractory metastatic disease, both as monotherapy and in combination with mitomycin C [27,28]. Another ongoing intergroup trial is comparing surgical or med ical castration plus an antiandrogen with or without suramin.…”

Section: Other Approachesmentioning

confidence: 99%

Combined Androgen Blockade

Crawford¹

1996

Eur Urol

View full text Add to dashboard Cite

Combined androgen blockade (CAB), the addition of an antiandrogen to castration (medical or surgical), is becoming a well-established option for advanced prostate cancer. CAB with leuprolide and flutamide was found to improve both progression-free and overall survival, compared with leuprolide alone, particularly in patients with minimal metastatic disease. These findings have led to an intergroup study in more than 1,300 men, including 300 with minimal disease, of orchidectomy with flutamide versus orchidectomy with placebo, which will examine which patient subgroups benefit most from CAB. This intergroup study has already provided important information regarding prostate-specific antigen as a surrogate marker for response and progression. The success with CAB in lengthening survival and improving quality of life in metastatic prostate cancer has stimulated enthusiasm for broadening the base of clinical studies for the management of this disease.

show abstract

“…R75251 enhances, dose-dependently, the retinoid acid concentration in se rum and tumours [78]. Suramin Suramin is a trypanocidal drug which also has a cyto static effect on prostate cancer cell lines [73][74][75], In the human cell lines PC3 and DU145, suramin exerts its cyto static effect by inhibiting the binding of growth factors to cell surface receptors [73]. It also reduces the specific binding of transforming growth factor-a to PC3 and DU 145 cells as well as increasing the percentage of cells in the S-phase of the cell cycle.…”

Section: Imidazole Derivativesmentioning

confidence: 99%

Advances and Trends in Hormonal Therapy for Advanced Prostate Cancer

Debruyne¹,

Dijkman²

1995

Eur Urol

View full text Add to dashboard Cite

Suramin in combination with mitomycin C in hormone-resistant prostate cancer. A phase II clinical study

Abstract: The combination of suramin and mitomycin C has therapeutic activity, but causes significant toxicity in patients with hormone-resistant prostatic carcinoma.

Cited by 17 publications

References 14 publications

Low-Dose Suramin Enhanced Paclitaxel Activity in Chemotherapy-Naïve and Paclitaxel-Pretreated Human Breast Xenograft Tumors

Low-Dose Suramin Enhanced Paclitaxel Activity in Chemotherapy-Naïve and Paclitaxel-Pretreated Human Breast Xenograft Tumors

Combined Androgen Blockade

Advances and Trends in Hormonal Therapy for Advanced Prostate Cancer

Contact Info

Product

Resources

About